
Q32 Bio Inc. — Investor Relations & Filings
Q32 Bio Inc. is a clinical-stage biotechnology company developing therapies to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company's therapeutic approach targets powerful regulators of both the innate and adaptive immune systems. Its most advanced product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody. Bempikibart is designed to re-regulate adaptive immune function by blocking signaling from both interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP). The candidate is currently being evaluated in a Phase 2 program for the treatment of alopecia areata.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| 10-Q - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | |
| 8-K - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | |
| ARS - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | |
| DEF 14A - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | |
| 424B5 - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-24 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47843637 | 8-K | 2026-05-27 | English | ||
| 41350292 | 10-Q - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | ||
| 41346460 | 8-K - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | ||
| 39072013 | ARS - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | ||
| 39069697 | DEF 14A - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | ||
| 36267508 | 424B5 - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-24 | English | ||
| 33003133 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 33003135 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 33003131 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 32896138 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 32896139 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 32896140 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 31187430 | 8-K Filing | 2026-02-17 | English | ||
| 31187392 | 424B5 Filing | 2026-02-17 | English | ||
| 31187419 | 4 Filing | 2026-01-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Burning Rock Biotech Ltd
A global diagnostics company specializing in precision onco…
|
BNR | US | Professional, scientific and te… |
|
Cabaletta Bio, Inc.
Develops engineered T cell therapies for B cell-mediated au…
|
CABA | US | Professional, scientific and te… |
|
Caliway
Develops small-molecule therapeutics for medical aesthetics…
|
6919 | TW | Professional, scientific and te… |
|
CALIX LIMITED
Develops industrial carbon capture and sustainable mineral …
|
CXL | AU | Professional, scientific and te… |
|
CAMBIUM BIO LIMITED
Clinical-stage developer of cellular therapies for ophthalm…
|
CMB | AU | Professional, scientific and te… |
|
CAMBRIDGE COGNITION HOLDINGS PLC
Develops digital solutions and a platform for CNS clinical …
|
COG | GB | Professional, scientific and te… |
|
CanBas Co.,Ltd.
A clinical-stage biopharmaceutical company developing novel…
|
4575 | JP | Professional, scientific and te… |
|
Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer …
|
CTX | PL | Professional, scientific and te… |
|
Cardiff Oncology, Inc.
A clinical-stage biotech developing cancer therapies that i…
|
CRDF | US | Professional, scientific and te… |
|
Cardio Diagnostics Holdings, Inc.
Develops AI-powered epigenetic and genetic tests for early …
|
CDIO | US | Professional, scientific and te… |
Q32 Bio Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34891/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34891 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34891 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34891 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34891}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Q32 Bio Inc. (id: 34891)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.